Biocartis Group NV (EBR: BCART)
Belgium flag Belgium · Delayed Price · Currency is EUR
0.290
0.00 (0.00%)
Nov 20, 2024, 9:00 AM CET

Biocartis Group NV Company Description

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology.

Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring.

The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.

It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays.

The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies.

It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform.

The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Biocartis Group NV
Biocartis Group NV logo
Country Belgium
Founded 2007
Industry Diagnostics & Research
Sector Healthcare
Employees 526
CEO Roger Moody

Contact Details

Address:
Generaal de Wittelaan 11 B
Mechelen, 2800
Belgium
Phone 32 1 563 26 00
Website biocartisgroupnv.be

Stock Details

Ticker Symbol BCART
Exchange Euronext Brussels
Fiscal Year January - December
Reporting Currency EUR
ISIN Number BE0974281132
SIC Code 3845

Key Executives

Name Position
Roger Moody Chief Executive Officer
Piet Houwen Chief Operating Officer
George A. Cardoza Chief Financial Officer and Head of Service Delivery
Benoit Devogelaere Chief Technology Officer
Geert Maertens Ph.D. Chairman of Scientific Advisory Board and Chief Scientific Officer
Renate Degrave Head of IR and Corporate Communications
Erik Vossenaar Ph.D. Senior Vice-President of Corporate Development and Strategy
Susy Spruyt Head of People and Organization
Dr. Erwin Sablon Head of Research & Development and Alliance Management
Reginald Van Genechten Head of Manufacturing and Supply Chain